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Atrial ﬁbrillation (AF) is the most common arrhythmia. Although AF is known to develop during the
course of various cardiac pathological conditions, including valvular heart diseases, congestive heart
failure, and hypertension, recent clinical data implicate the additional contribution of genetic factors in
the pathogenesis of AF. A familial form of AF has been noted, and 8 loci and 6 responsible genes have been
identiﬁed. In non-familial AF, genetic risks were originally investigated by the candidate gene approach,
and recently by genome-wide association studies (GWASs). GWASs executed in other countries have
identiﬁed 3 loci: 4q25 near Pitx2, 1q21 in KCNN3, and 16q22 in ZFHX3. Several AF-associated SNPs in 4q25
are also associated with the recurrence rate of AF after catheter pulmonary vein isolation. This review will
discuss the genetic underpinnings of AF, in both familial AF and non-familial AF.
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Atrial ﬁbrillation (AF) is the most common arrhythmia[1]. Pre-
viously, AF was believed to develop during the course of various
cardiac pathological conditions, including valvular heart diseases,
congestive heart failure, and hypertension. Recent clinical data,
however, implicate the involvement of genetic factors in pathogen-
esis of AF. A familial form of AF has been noted, and several
responsible genes have been identiﬁed. A recent study found a
positive family history in 5% of AF patients referred to an arrhythmia
clinic, including 15% of patients with lone AF, suggesting that
familial AF may be more common than previously thought[2].rt Rhythm Society. Published by E
Furukawa).Furthermore, in the Framingham Heart Study, individuals with a
parental history of AF had an increased risk of developing AF
themselves (multivariable-adjusted odds ratio, 1.85; 95% conﬁdence
interval [CI], 1.12–3.06) [3]. Thus, the genetic background may
underlie the pathogenesis of AF in both familial and non-familial AF.2. Familial AF
Although familial AF, a monogenetic heterogenous disorder with
a Mendelian inheritance pattern, is uncommon, it has been noted
since its ﬁrst report in 1943 [4]. However, attention to the genetic
background of familial AF was stimulated by a report by Brugada
et al. in 1997 [5]. This report described 3 families with apparent
autosomal dominant transmission of AF, and demonstrated linkagelsevier B.V. All rights reserved.
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linkage to 8 loci has been described, and 6 responsible genes have
been identiﬁed within these loci (Table 1). The identiﬁed genes
include those encoding potassium and sodium channels that are also
known to cause other allelic diseases such as long QT syndrome and
short QT syndrome, and NPPA encoding atrial natriuretic peptide
(ANP). Experimentally, an increase in ANP levels is known to result
in electrophysiological derangements in atrial myocytes [13].3. Candidate gene approach in non-familial AF
The fact that parental AF is a risk factor for the development of
AF in offspring in non-familial AF [3] suggests the presence of a
genetic component for non-familial AF as well. To identify genetic
risk factors in non-familial AF, candidate gene approaches were
originally undertaken, and at least 13 nuclear genes and 1 mito-
chondrial gene were found to be associated with AF, including
those encoding renin-angiotensin factors, connexin (Cx), and
inﬂammatory proteins (Table 2).
The renin-angiotensin system plays a crucial role in atrial
ﬁbrosis, which is a key pathological consequence of AF. Genes
encoding 3 molecules related to the renin-angiotensin system,
including angiotensin-converting enzyme (ACE), angiotensinogen,
and angiotensin type 1 receptor (AT1R), are associated with AF
[21,22].
Electrical coupling is vital to atrial myocytes, and this is provided
by intercellular channels termed Cxs. Among these, C40 (GJA5) is
selectively found in the atria and in the His-Purkinje system. Juang
et al. found that a GJA5 haplotype (44 Aþ71 G), common to the
population was associated with a signiﬁcantly higher risk for AF
[24]. Interestingly, 4 mutations in GJA5 were found in genomic DNA
isolated from atrial tissue specimens from patients with lone AF, butTable 1
Genetics in familial AF.
Gene Mutation Locus Mode of inheritance References
Unknown 10q22–24 A.D. [5]
Unknown 6q14–16 A.D. [6]
KCNE2 R27C 21q22.1 A.D. [7]
KCNH2 N588K 7q35–36 A.D. [8]
KCNJ2 V93I 17q23.1–24.2 A.D. [9]
KCNQ1 R14C, S140G 11p15.5 A.D. [10]
NPPA 1p36.2 A.D. [11]
KCNA5 E375X 12p13 A.D. [12]
A.D., autosomal dominant.
Table 2
Candidate genes responsible for non-familial AF.
Gene Genotype
KCNE1 A112G, S38G
GNB3 C825T
SCN5A A1867G, H558R,D1275N
SLN G-65C
ACE ACE-I/D
AGT G-6 A, A-20C, G-152 A, G-217 A
ARTR1 A1166C
GJA5 44 A/þ71 G, 44 G/þ71 A P88S, M163V, G38D, A96S
NOS3 T-786C, G894T, E298D
MMP2 C-1306 T
IL1B C511T
IL10 A-592C
IL6 C174G
mtDNA 4977 bp (from 8470–13446) deletionthese mutations were absent from genomic DNA isolated from the
lymphocytes of these patients [25]. These results suggest that in
addition to traditional germline mutations, somatic mutations might
also play an important role in a predisposition towards AF.
AF patients have high sensitive CRP levels [30], and chronic
inﬂammation plays a role in AF pathogenesis. Genes encoding
3 pro-inﬂammatory cytokines, IL-1b, IL-6, and IL-10, are found to
be associated with AF [26–28]. AF is a frequent complication of
open-chest surgery. Gaudino et al. found that the 174 G/C IL-6
polymorphism determines postoperative levels of IL-6; those
with the GG genotype have a higher incidence of AF compared
to those without the GG genotype (33.9% vs. 10.4%; hazard ratio,
3.25; 95% CI 1.23–8.62) [28].
The risk for AF development increases with increasing age. A
common type of mitochondrial DNA (mtDNA) deletion mutation,
a 4977-bp deletion mutation from base pairs 8470 and 13446
(mtDNA4977) [31], has been used as a general index of somatic
mtDNA mutations, and has been reported in various tissues from
aging humans [32]. The presence of mtDNA deletion mutations
appears to be a risk factor for AF in older populations. Lai et al.
found that the relative amount of mtDNA4977 was signiﬁcantly
higher in patients with AF than in patients without AF in older
populations, but not in children or adolescents[29].
It is important to note, however, that the majority of these
candidate gene approaches have been substantially underpow-
ered, and have not been replicated in independent populations or
in different ethnic groups. Further studies in large patient cohorts
are clearly warranted.4. What is GWAS
About 3–10 million variants are assumed to be present in the
entire human genome, which consists of about 30 billion base
pairs. As with the genotype, the pattern of variants is termed as the
haplotype. Homologous recombination does not occur randomly
over the whole genome. Instead, it occurs at the certain sites,
referred to as homologous recombination hot spots. The region
from one homologous recombination hot spot to the next is called
the haplo-block, in which variants rarely exchange (Fig. 1). If
variants A and B are present within a single haplo-block, then
the presence of variant A indicates a very high probability
(usually490%) of the presence of variant B. In contrast, the
absence of variant A indicates a very low likelihood of the presence
of variant B. Such variants that show similar transmission char-
acteristics are claimed to be in linkage disequilibrium (LD). Because
of the presence of LD, only about 10% of all variants (about 0.3–1.0
million variants) need to be analyzed in order to assess theProtein References
b-subunit of IKs [14,15]
Regulatory protein of IK(Ach) [16]
a-subunit of INa [17,18]
Sarcolipin, an inhibitor of SERCA [19,20]
angiotensin 1-converting enzyme [21,22]
angiotensinogen [21,22]
angiotensin1 receptor, type 1 [21,22]
Cx40 [23–25]
eNOS (endothelial type NO synthase) [15]
matrix metalloproteinase-2 [26]
IL-1b [26]
IL-10 [27]
IL-6 [28]
mitochondrial DNA [29]
Fig. 1. Linkage disequilibrium (LD). The combination of 4 SNPs (SNP A–D) transmitted from one generation to the next is illustrated. If the homologous recombination
hotspot is present between SNP-A and SNP-B, and between SNP-C and SNP-D, SNP B and SNP-C are transmitted similarly to the next generation, and are referred to be in
linkage disequilibrium (LD).
Table 3
Results of GWASs.
Locus SNP Adjacent
gene
OR 95% CI P-value Reference
4q25 rs2200733 Pitx2 1.72 1.59– 3.31041 [33]
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it is possible to analyze up to 1 million variants simultaneously.
The analysis of up to 1 million variants in the entire genome (most
frequently 610,000 SNPs) is called a GWAS (genome-wide associa-
tion study), and is widely employed in the study of various
common diseases.1086
rs10033464 Pitx2 1.39 1.26–1.53 6.91011 [33]
rs6843082 Pitx2 2.03 1.79–2.30 2.51028 [34]
rs17042171 Pitx2 1.65 1.55–1.75 3.91063 [35]
1q21 rs13376333 KCNN3 1.52 1.40–1.74 1.831021 [36]
16q22 rs2106261 ZFHX3 1.25 1.19–1.33 1.81015 [37]
OR, odds ratio; 95% CI, 95% conﬁdence interval.5. GWAS for AF
The result of a GWAS for AF was ﬁrst reported from the Decode
project in 2007 [33]. This study analyzed the association of
316,515 SNPs in 550 AF/atrial ﬂutter (AFL) patients and 4,476
controls from Iceland. The researchers found associations
between AF/AFL and several SNPs in the 4q25 region. Since then,
2 other loci associated with AF have been identiﬁed, one in 1q21
[34] and the other in 16q22[36].
Although no GWAS results have been reported so far from
Asian populations, the candidate gene approach identiﬁed SNPs in
4q25 and 1q21 as being associated with AF in Asian populations
[19,20]. Conﬂicting data are reported in terms of 16q22; it is
associated with AF in Chinese Han [37], but not in Hong Kong
[33]. A summary of GWAS results thus far is presented in Table 3.
A GWAS is currently underway in the Japanese population, and
the results will be reported in the near future.6. Biological signiﬁcance of GWAS results
The biological signiﬁcance of the results of GWAS has not been
thoroughly examined.
The most signiﬁcant SNP identiﬁed in almost all GWASs is
present in the gene-desert region, with a transcription factor, Pitx2,
as the closest gene. There are 3 isoforms of the Pitx2 product,
Pitx2a, b, and c. Among them, Pitx2c is most abundantly expressed
in the heart. Pitx2c is expressed only in the left side of the heart and
determines the left-to-right difference in the heart [38].
During the course of heart development, the sinus node-like
region that generates spontaneous electrical excitation is present
both in the primitive right atrium and the left atrium. When
Pitx2c is expressed only in the left atrium at 11.5 day after
fertilization, the sinus node-like region in the primitive leftatrium disappears and the sinus node becomes localized in the
right atrium (Fig. 2) [39].
Currently, the triggering event for AF is believed to be
abnormal electrical activity in the myocardial sleeve in the
pulmonary vein in the majority of AF cases [40]. Pitx2c plays
an important role in the development of the myocardial sleeve
(Fig. 3) [41]. The myocardial sleeve develops from the mesench-
ymal tissue present around the precursors of the pulmonary
veins. Until 10.5 day after fertilization, the precursors of pulmon-
ary veins are surrounded by mesenchymal tissue. When Pitx2c is
expressed at 11.5 day, Pitx2c induces the differentiation of the
mesenchymal tissue into the myocardium. When Nkx2.5 is
expressed at 12.5 day, Pitx2c and Nkx2.5 co-operate to stimulate
the proliferation of the myocardium along the pulmonary vein
towards the lung, thereby generating the myocardial sleeve
around the pulmonary veins (Fig. 3).
It is not clear whether SNPs in 4q25 near the Pitx2 gene act on
AF pathogenesis via the abnormal suppression of sinus node-like
automaticity in the left atrium, or abnormal development of the
pulmonary vein myocardial sleeve, or both.
The other 2 SNPs associated with AF are located in 1q21 (in
KCNN3) and in 16q22 (in ZFHX3). The functional association of
ZFHX3 with AF is totally unknown. KCNN3 encodes the Ca2þ
activated Kþ channel that has a small single-channel conductance
(SK channel). Within the heart, the SK channel is mainly localized in
the atrium, and activation of SK channels contributes to the short-
ening of the potential duration of atrial action [42], and thereby to
the induction of AF. Discovery and development of SK channel
inhibitors are currently underway as a new class of anti-AF agent.
Fig. 2. Role of Pitx2c in sinus node localization in the right atrium. Left: In the primitive atrium at 10.5 day after fertilization, both right and left atria have sinus node (SN)-
like tissue. Right:When Pitx2c is expressed only in the left atrium at 11.5 day after fertilization, the SN-like tissue in the left atrium disappears.
Fig. 3. Role of Pitx2c in the generation of the myocardial sleeve. Left:At 10.5 day after fertilization, mesenchymal tissue is present around the precursors of pulmonary
veins. Middle:When Pitx2c is expressed after 11.5 day, mesenchymal tissue around the precursors of pulmonary veins differentiates into myocardium. Right:When Nkx2.5
expresses at 12.5 day and later, Pitx2c and Nkx2.5 co-operate to stimulate the proliferation of myocardium along the pulmonary vein toward the lung.
Fig. 4. SNPs in 4q25 related to AF recurrence after PVI.AF recurrence after PVI was
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The catheter technique for pulmonary vein isolation (PVI) is
routinely used for the treatment and management of AF. The
recurrence rate of AF after PVI varies from hospital to a hospital,
mainly depending on whether PVI is applied to chronic AF or not,
the maximum duration of AF for which PVI is applied, and
whether the complex atrial fractionated electrogram-based
approach is employed or not. Nevertheless, the recurrence rate
appears to be roughly 40–50% after single procedure, and 10–20%
after multiple procedures. Husser et al. examined if SNPs in 4q25
correlate with post-PVI recurrence of AF [43]. They analyzed 195
consecutive patients with drug-refractory paroxysmal or persis-
tent AF who underwent PVI. The recurrence at 6 months was 21%;
that in patients with any 4q25 SNP was 38%, whereas that in
patients without 4q25 SNPs was 8% (p¼0.007) (Fig. 4). Although
the data is limited and has not been replicated, the data suggest
that 4q25 SNPs can be used to stratify the risk of AF recurrence
after PVI.signiﬁcantly greater in individuals with 4q25 variants than those without 4q25
variants.8. Conclusion
Accumulating clinical data suggest the presence of a genetic
component in the pathogenesis of AF. In addition to the gene
mutations identiﬁed in familial AF, the candidate gene approach
and GWAS identiﬁed genetic risks in the non-familial form of AF. Inmultiple Western populations, GWASs identiﬁed 3 loci associated
with AF; 4q25 with Pix2 as the closest gene, 1q21 in KCNN3, and
16q22 in ZFHX3. SNPs in 4q25 may be useful in risk stratiﬁcation of
AF recurrence after PVI, and inhibitors of SK channels encoded by
KCNN3 are considered to be novel pharmacological therapeutics for
T. Furukawa, Y. Ebana / Journal of Arrhythmia 28 (2012) 140–144144AF. However, the functional relevance of these genetic risks, their
clinical implications, and their status in the Japanese population
are yet to be fully clariﬁed, and require further study.Conﬂict of interest
None declared.Note added in proof
After submission of this manuscript, international meta-ana-
lysis of AF GWAS including Japanese one has been published [44].
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